Portola Pharmaceuticals present new data from betrixaban and AndexXa studies

Portola Pharmaceuticals presented data from its pivotal Phase 3 APEX study for the investigational drug betrixaban. | Contributed image

Portola Pharmaceuticals Inc. presented data from its pivotal Phase 3 APEX study for the investigational drug betrixaban at a poster session at the American College of Cardiology’s (ACC) 66th Annual Scientific Session & Expo. 

Betrixaban is an oral, once-daily Factor Xa inhibitor anticoagulant that seeks to extend prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. It is being fast-tracked by the U.S. Food and Drug Administration.

The company also presented information on the investigational agent AndexXa (andexanet alfa) at an oral session titled, “Challenging the Standard of Care: Emerging Concepts in VTE Treatment and Prevention.”

AndexXa, an FDA-designated Breakthrough Therapy, is being developed for patients treated with a direct (apixaban, rivaroxaban or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor. Specifically, the drug will be used when life-threatening or uncontrolled bleeding creates a need for the reversal of anticoagulation.

The ACC event was held at the Walter E. Washington Convention Center in Washington, D.C.

Want to get notified whenever we write about Portola Pharmaceuticals ?
Next time we write about Portola Pharmaceuticals, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Portola Pharmaceuticals 270 East Grand Avenue South San Francisco, CA 94080